Adcomm splits slightly in favor of FDA approving ChemoCentryx’s rare disease drug

Submitted by admin on May 6, 2021 - 11:06pm

Source:

Endpoints

News Tags:

FDA

advisory panels

ChemoCentryx

avacopan

ANCA-positive vasculitis

Headline:

Adcomm splits slightly in favor of FDA approving ChemoCentryx’s rare disease drug

snippet:

The FDA’s Arthritis Advisory Committee on Thursday voted 10 for and 8 against the approval of ChemoCentryx’s $CCXI investigational drug avacopan as a treatment for adults with a rare and serious disease known as anti-neutrophil cytoplasmic autoantibody (ANCA)-vasculitis.

Search form

You are here

Adcomm splits slightly in favor of FDA approving ChemoCentryx’s rare disease drug

Adcomm splits slightly in favor of FDA approving ChemoCentryx’s rare disease drug